Dr KSS wrote about SCYX last month. He explained how they have an anti-fungal drug underway that would be very helpful as an adjunct to the many anti-bacterial drugs already on the market. An anti-fungal would be a bit unique and therefore valuable, he explained. However, I just read that SCYX sold their product (all their cyclophilin inhibitor assets). Does this mean they just sold out of their rights to the anti-fungal material Dr. KSS was discussing?
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.